KAS
DERM icon

Kestra Advisory Services’s Journey Medical DERM Stock Holding History

Kestra Advisory Services’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,209
Closed -$72.7K – 4552
2025
Q3 		$72.7K Buy
+10,209
New +$74K ﹤0.01% 2840
2025
Q1 		– Sell
-15,000
Closed -$58.6K – 2788
2024
Q4 		$58.6K Buy
+15,000
New +$82K ﹤0.01% 2602

Other funds holding DERM

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PFCS
Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Kestra Advisory Services's DERM Position: Q4 2025 in Review

Kestra Advisory Services sold out of Journey Medical (DERM) in Q4 2025, closing a stake of 10,209 shares — an estimated $72.7K sold.

Kestra Advisory Services first reported a position in DERM in Q4 2024 and held it in 2 quarters. The position peaked at $72.7K in Q3 2025. 77 funds tracked by Wall St. Rank hold DERM as of Q4 2025.

  • Kestra Advisory Services reported no remaining Journey Medical position as of Q4 2025 after selling out during the quarter.
  • Kestra Advisory Services sold 10,209 Journey Medical shares in Q4 2025, an estimated $72.7K.
  • Kestra Advisory Services first reported a position in Journey Medical in Q4 2024 and held it in 2 quarters.
  • Kestra Advisory Services's Journey Medical position peaked at $72.7K in Q3 2025.
  • 77 funds tracked by Wall St. Rank held Journey Medical as of Q4 2025.

Based on Kestra Advisory Services's 13F filing for Q4 2025, filed 13 Feb 2026.